On August 19, 2019 Genmab A/S (Nasdaq: GMAB) reported that 13 Janssen Research & Development, LLC (Janssen)-sponsored abstracts regarding daratumumab were accepted for presentation at the 17th International Myeloma Workshop, taking place in Boston, Massachusetts from September 12 to 15, 2019 (Press release, Genmab, AUG 19, 2019, View Source [SID1234538874]). Data from the Phase II GRIFFIN study (MMY2004) and data from the Phase II PLEIADES (MMY2040) study were both accepted for presentation during oral sessions at the conference. The abstracts are available on the conference website and may be accessed via View Source
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We look forward to the first presentation of data from the Phase II PLEIADES and GRIFFIN studies and are pleased to see that key updates from the Phase III MAIA, CASSIOPEIA and COLUMBA studies, have all been selected for presentation at a prestigious medical conference," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
Abstracts submitted by Janssen include:
Daratumumab, Lenalidomide, Bortezomib and Dexamethasone Improves Depth of Response in Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN – Oral presentation, Sunday, September 15, 8:45 AM EDT
Concordance of Post-consolidation Minimal Residual Disease Rates by Multiparametric Flow Cytometry and Next-generation Sequencing in CASSIOPEIA – Oral presentation, Friday, September 13,10:45 AM EDT
Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone in Transplant-eligible Newly Diagnosed Multiple Myeloma: Subgroup Analysis of High-risk Patients in CASSIOPEIA -Oral presentation, Friday, September 13, 10:30 AM EDT
Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma (MM) Treatment Regimens: An Open-label, Multicenter Phase 2 Study (PLEIADES) – Oral presentation, Friday September 13, 1:45 PM EDT
Greater Treatment Satisfaction in Patients Receiving Subcutaneous Versus Intravenous Daratumumab for Relapsed or Refractory Multiple Myeloma: COLUMBA – Poster discussion presentation, Saturday, September 14, 12:30 PM – 2:00 PM EDT
Results of the Daratumumab Monotherapy Early Access Treatment Protocol in Patients from Brazil with Relapsed or Refractory Multiple Myeloma – Poster discussion presentation, Saturday, September 14, 12:30 PM – 2:00 PM EDT
Daratumumab, Lenalidomide, and Dexamethasone Delivers a Reduction and Delay in Worsening of Pain Symptoms for Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplant – Poster presentation, Saturday, September 14, 12:30 PM – 2:00 PM EDT
A Matching-adjusted Indirect Comparison of Bortezomib-Thalidomide-Dexamethasone and Daratumumab Plus Bortezomib-Thalidomide-Dexamethasone Versus Bortezomib-Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma who are Transplant Eligible – Poster presentation, Saturday, September 14, 12:30 PM – 2:00 PM EDT
A Matching-adjusted Indirect Comparison of Daratumumab-Bortezomib-Thalidomide-Dexamethasone Versus Bortezomib-Lenalidomide-Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma who are Transplant Eligible – Poster presentation, Saturday, September 14, 12:30 PM – 2:00 PM EDT
A Matching-adjusted Indirect Comparison of Bortezomib-Thalidomide-Dexamethasone and Daratumumab Plus Bortezomib-Thalidomide-Dexamethasone Versus Bortezomib-Cyclophosphamide-Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma who are Transplant Eligible – Poster presentation, Saturday, September 14, 12:30 PM – 2:00 PM EDT
Subcutaneous Daratumumab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: An Open-label, Multicenter, Phase 2 Study (PLEIADES) – Trial-in-progress poster presentation, Friday, September 13, 6:30 PM – 8:30 PM EDT
Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma After Frontline Transplant: A Multicenter, Randomized, Phase 3 Study (AURIGA) – Trial-in-progress poster presentation, Saturday, September 14, 12:30 PM – 2:00 PM EDT
A Randomized Phase 2 Study of Subcutaneous Daratumumab Plus Carfilzomib/Dexamethasone Versus Carfilzomib/Dexamethasone Alone in Patients with Multiple Myeloma who have been Previously Treated with Intravenous Daratumumab to Evaluate Retreatment (LYNX) – Trial-in-progress poster presentation, Saturday, September 14, 12:30 PM – 2:00 PM EDT
In August 2012, Genmab granted Janssen Biotech, Inc. an exclusive worldwide license to develop, manufacture and commercialize daratumumab.